{
    "clinical_study": {
        "@rank": "33690", 
        "arm_group": {
            "arm_group_label": "Treatment (flavopiridol)", 
            "arm_group_type": "Experimental", 
            "description": "Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.\nPatients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of flavopiridol in treating patients who have\n      chronic lymphocytic leukemia that has not responded to treatment with fludarabine. Drugs\n      used in chemotherapy use different ways to stop cancer cells from dividing so they stop\n      growing or die"
        }, 
        "brief_title": "Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia", 
        "condition": [
            "B-cell Chronic Lymphocytic Leukemia", 
            "Refractory Chronic Lymphocytic Leukemia", 
            "Stage I Chronic Lymphocytic Leukemia", 
            "Stage II Chronic Lymphocytic Leukemia", 
            "Stage III Chronic Lymphocytic Leukemia", 
            "Stage IV Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:   Determine the complete and partial response rate to flavopiridol in patients\n      with fludarabine-refractory chronic lymphocytic leukemia.\n\n      Assess the toxicity profile of this treatment in these patients. Examine progression-free\n      survival and overall survival following this treatment in these patients.\n\n      Determine the effects of flavopiridol on normal T-cell subsets and immunoglobulin levels in\n      these patients.\n\n      OUTLINE: This is an open label, multicenter study.\n\n      Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3.\n      Treatment repeats every 14 days for a total of 12 courses in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3.\n      Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease\n      progression or unacceptable toxicity.\n\n      Patients are followed every 3 months for the first year and then every 6 months for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically diagnosed intermediate risk (stage I or II) or high risk (stage III or\n             IV) refractory B-cell chronic lymphocytic leukemia\n\n          -  Intermediate risk group must have evidence of active disease as shown by at least one\n             of the following:\n\n               -  Massive or progressive splenomegaly and/or lymphadenopathy\n\n               -  Weight loss of greater than 10% in the last 6 months\n\n               -  CALGB grade 2-4 fatigue\n\n               -  Fevers greater than 100.5 degree Fahrenheit OR night sweats for greater than2\n                  weeks without evidence of infection\n\n               -  Progressive lymphocytosis with an increase greater than 50% over a 2 month\n                  period or an anticipated doubling time of less than 6 months\n\n          -  Refractory to fludarabine treatment OR relapsed within 6 months of fludarabine\n\n          -  Lymphocytosis greater than 5000/mm3 at some time during disease\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  Creatinine no greater than 1.5 times ULN\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No more than 1 prior nonradiolabeled antibody treatment (e.g., Campath-1H or\n             rituximab)\n\n          -  At least 1, but no more than 3, prior chemotherapy regimens\n\n          -  At least 1 prior chemotherapy regimen comprising fludarabine\n\n          -  No other concurrent chemotherapy\n\n          -  No concurrent chronic use of oral corticosteroids\n\n          -  No concurrent hormone therapy except for non-disease related conditions\n\n          -  No concurrent dexamethasone or other corticosteroid-based antiemetics\n\n          -  No concurrent palliative radiotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003620", 
            "org_study_id": "NCI-2012-02280", 
            "secondary_id": [
                "CALGB-19805", 
                "U10CA031946", 
                "CDR0000066699"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (flavopiridol)", 
                "description": "Given IV", 
                "intervention_name": "alvocidib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FLAVO", 
                    "flavopiridol", 
                    "HMR 1275", 
                    "L-868275"
                ]
            }, 
            {
                "arm_group_label": "Treatment (flavopiridol)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Flavopiridol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60606"
                }, 
                "name": "Cancer and Leukemia Group B"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE II STUDY OF FLAVOPIRIDOL (NSC # 649890) IN PATIENTS WITH PREVIOUSLY TREATED BCELL CHRONIC LYMPHOCYTIC LEUKEMIA", 
        "overall_official": {
            "affiliation": "Cancer and Leukemia Group B", 
            "last_name": "John Byrd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The CR + PR rate will be estimated with a 95% confidence interval, and the success of the study will be judged with the two-stage design given above.", 
            "measure": "Complete + partial response rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicities will be tabulated by type and grade", 
                "measure": "Toxicity profile of flavopiridol", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Will be estimated using the Kaplan-Meier method.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "From onstudy date to the date of progression or death, assessed up to 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From onstudy date to the date of death, assessed up to 5 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Cancer and Leukemia Group B": "41.878 -87.63"
    }
}